Buscador de Revistas

Special Issue Call For Papers! Evidence Based Practice: Using EBCAI Effectively Psychology Press is pleased to announce Evidence-Based Communication Assessment and Intervention - an international journal under the joint editorship of Dr. Ralf W. Schlosser, Professor, Department of Speech-Language Pathology and Audiology, Northeastern University, Boston, U.S.A., and Dr. Jeff Sigafoos, Professor, Victoria University of Wellington, New Zealand.Evidence-Based Communication Assessment and Intervention (EBCAI) brings together professionals from several disciplines to promote evidence-based practice (EBP) in serving individuals with communication impairments. We target speech-language pathologists, special educators, regular educators, applied behavior analysts, clinical psychologists, physical therapists, and occupational therapists who serve children or adults with communication impairments. We select and appraise the latest and highest quality studies and reviews related to assessment, intervention, diagnosis, and prognosis published across 60+ professional journals in speech-language pathology and related fields. We make these appraisals accessible through value-added structured abstracts that include expert commentary about the quality of the evidence as well as its practical implications. This affords the practitioner a one-stop reading experience to stay on top of research findings in order to facilitate evidence-based decision-making. Researchers and university professors will benefit from access to cutting-edge and clinically relevant studies.EBCAI also provides a forum for the dissemination of original research and discussion of methodologies and concepts that advance EBP as well as of experiential accounts of relevant stakeholders involved in the EBP process. Please consult the Information for Authors for the specific kinds of submissions EBCAI seeks to publish. Special IssuesIssues devoted to a single topic are regularly published in this journal; these are sent free to subscribers in that year, and are also available to purchase separately as books for non-subscribers. Click on the title below for more information and to order.Teaching Evidence-Based PracticeEditors: Ralf Schlosser and Jeff SigafoosVolume 3, Issue 4 (2009) ISBN 978-1-84872-730-4Related LinksBrowse books in Speech & Communication Disorders, and view forthcoming conferences in Language Disorders.Disclaimer Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in its publications. However, Taylor & Francis and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether expressed or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not the views of Taylor & Francis.

Evidence-Based Practice in Child and Adolescent Mental Health is an official journal of the Society of Clinical Child and Adolescent Psychology (Division 53), American Psychological Association. The journals seeks to:

(a) Describe the breadth, expertise, and diversity of the field of clinical child and adolescent psychology;

(b) Provide a source of explicating the findings and methods from scientific studies in applied and diverse settings;

(c) Advocate and illuminate the unique and expert knowledge, skill, and experience of clinical child and adolescent psychologists;

(d) Provide a resource for the sharing of ideas, activities, outcomes, and applications of the applied skills and experiences clinical child and adolescent psychologists. 

The purpose of Exceptionality is to provide a forum for presentation of current research and professional scholarship in special education. Areas of scholarship published in the journal include quantitative, qualitative, and single-subject research designs examining students and persons with exceptionalities, as well as reviews of the literature, discussion pieces, invited works, position papers, theoretical papers, policy analyses, and research syntheses. Appropriate data-based papers include basic, experimental, applied, naturalistic, ethnographic, and historical investigations. Papers that describe assessment, diagnosis, placement, teacher education, and service delivery practices will also be included. Manuscripts accepted for publication will represent a cross section of all areas of special education and exceptionality and will attempt to further the knowledge base and improve services to individuals with disabilities and gifted and talented behavior.Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

The first issue of Exemplaria, with an article by Jacques Le Goff, was published in 1989. Since then the journal has established itself as one of the most consistently interesting and challenging periodicals devoted to Medieval and Renaissance studies. Providing a forum for different terminologies and different approaches, it has included symposia and special issues on teaching Chaucer, women, history and literature, rhetoric, medieval noise, and Jewish medieval studies and literary theory. The Times Literary Supplement said of Exemplaria that 'it breaks into new territory, while never compromising on scholarly quality'.

Experimental Aging Research is a life span developmental and aging journal dealing with research on the aging process from a psychological and psychobiological perspective. It meets the need for a scholarly journal with refereed scientific papers dealing with age differences and age changes at any point in the adult life span. Areas of major focus include experimental psychology, neuropsychology, psychobiology, work research, ergonomics, and behavioral medicine. Original research, book reviews, monographs, and papers covering special topics are published. Peer Review Policy: All review papers in this journal have undergone editorial screening and peer review. Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

Experimental Heat Transfer provides a forum for experimentally based high quality research articles and communications in the general area of heat-mass transfer and the related fluid dynamics. In addition to the established multifaceted areas of thermal energy conversion and transport that are intimately connected to heat transfer related research, the journal also communicates contributions from new and emerging areas of research such as micro- and nanoscale science and technology, life sciences and biomedical engineering, manufacturing processes, materials science, and engineering. In all of these areas heat transfer plays an important role, in particular, in the form of innovative experiments and systems for direct measurements and analysis, as well as to verify or complement theoretical models. All contributions to the journal add to the knowledge base in heat transfer from the standpoint of fundamentals or applications. All papers are thoroughly peer refereed. Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

Aims & ScopeWelcome to Experimental Mathematics, a journal devoted to experimental aspects of mathematics research. It publishes original papers featuring formal results inspired by experimentation, conjectures suggested by experiments, and data supporting significant hypotheses. Experimental Mathematics, refereed in the traditional manner, is led by a first-rate editorial board. A high standard of exposition is maintained, in order to reach as many readers as possible.

Expert Opinion on Biological Therapy ranks #42 of 160 in the Biotechnology & Applied Microbiology category and #30 of 106 in the Medicine, Research & Experimental category in the 2009 ISI Journal Citation Reports.Expert Opinion on Biological Therapy (ISSN 1471-2598 [print], 1744-7682 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on all aspects of biological therapy, providing expert opinion on the scope for future development.The Editors welcome: * Reviews covering gene therapy and gene transfer technologies; therapeutic peptides and proteins; vaccines and antibodies; cell- and tissue-based therapies * Drug Evaluations reviewing the clinical data on a particular biological agent * Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practiceThe audience consists of scientists and managers in the healthcare and biopharmaceutical industry and others closely involved in the development of biological therapy for the treatment of human disease.

Expert Opinion on Drug Delivery ranks #32 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders * Technology Evaluations reviewing a particular drug delivery technologyThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents.

Expert Opinion on Drug Discovery ranks #176 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology * Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug * Perspectives on topical issues with potential impact on the future of drug discoveryThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.

Expert Opinion on Drug Metabolism & Toxicology ranks #66 of 249 in the Pharmacology & Pharmacy category and #112 of 286 in the Biochemistry and Molecular Biology category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data * Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drugThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.

Expert Opinion on Drug Safety ranks #100 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development. * Reviews covering occurrence, management and prevention of drug-associated adverse events; risk-benefit analyses of individual drugs and drug classes; safety in 'at-risk' patient populations; comparative tolerability studies; pharmacovigilance and pharmacoepidemiological studies * Drug Safety Evaluations reviewing the safety data on a particular drug * Original Research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes; methods for the detection and evaluation of drug-associated adverse eventsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.Read More: http://informahealthcare.com/page/Description?journalCode=eds.

Expert Opinion on Emerging Drugs ranks #69 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.Each review article is structured to include: * Concise background to the subject matter * Assessment of medical need for alternative or novel therapies * Assessment of the market and anticipated changes over time * Summary of current research goals * Outline of the scientific rationale for the approach(es) considered< * Analysis of the competitive environment * Discussion of potential development issues * The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseasesThe audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners.

Expert Opinion on Investigational Drugs ranks #35 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. * Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Expert Opinion on Orphan Drugs will be an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.

Expert Opinion on Pharmacotherapy ranks #120 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.The Editors welcome: * Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practiceThe audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.